On December 17, 2019 Aethlon Medical, Inc. (Nasdaq: AEMD) (the "Company"), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported the closing of the previously announced underwritten public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share (Press release, Aethlon Medical, DEC 17, 2019, View Source [SID1234552446]). Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has also granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock and/or common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

The gross proceeds of the offering are approximately $5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses and excluding the exercise of any common warrants and the underwriter’s option to purchase additional securities. The Company intends to use approximately $700,000 of the net proceeds from this offering for the currently planned clinical trials for the Hemopurifier over the next 12 months, with the remainder for working capital and other general corporate purposes.

A registration statement on Form S-1 (File No. 333-234712) relating to these securities (and the shares of common stock underlying the common warrants and pre-funded warrants) was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on December 12, 2019. This offering was made only by means of a prospectus forming part of the effective registration statement. A final prospectus relating to and describing the terms of the offering has been filed with the SEC and copies may be obtained for free by visiting the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to the offering may also be obtain by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at 646-975-6996.

At the closing of the offering, the Company has 3,237,522 outstanding shares of common stock, assuming no exercise of any pre-funded warrants and warrants issued in the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aethlon and the Hemopurifier

Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier depletes the presence of circulating tumor-derived exosomes that promote immune suppression.

These tumor derived exosomes also seed the spread of metastases and inhibit the benefit of leading cancer therapies. The Hemopurifier is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.

On December 17, 2019 Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") reported that it has priced its previously announced offering of $1,250,000,000 aggregate principal amount of 5.000% senior notes due 2028 (the "2028 Notes") and $1,250,000,000 aggregate principal amount of 5.250% senior notes due 2030 (the "2030 Notes" and, together with the 2028 Notes, the "Notes") (Press release, Bausch Health, DEC 17, 2019, View Source [SID1234552445]). The aggregate size of the offering of the Notes is $2,500,000,000, which reflects an increase of $1,250,000,000 from the previously announced offering size of $1,250,000,000. The 2028 Notes will be sold to investors at a price of 100% of the principal amount thereof and the 2030 Notes will be sold to investors at a price of 100% of the principal amount thereof. Bausch Health intends to use the proceeds from the offering of the Notes, along with cash on hand, to finance amounts owed under the Company’s recently announced $1.21 billion settlement agreement (the "Settlement") relating to the U.S. putative securities class litigation filed in the U.S. District Court for the District of New Jersey (which is subject to court approval), and redeem $1.24 billion aggregate principal amount of the Company’s outstanding 5.875% Senior Notes due 2023, as well as to pay related fees and expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Company’s credit agreement and existing senior notes. Consummation of the offering of the Notes is subject to various closing conditions, and there can be no assurance that the Company will be able to successfully complete this transaction on the terms described above, or at all.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

On December 17, 2019 Colorado’s life sciences ecosystem reported that it raised $750 million in 2019, with funds from federal and state grants, successful financing rounds and acquisitions (Press release, Colorado Life Sciences, DEC 17, 2019, View Source [SID1234552444]). The record-breaking acquisition of Boulder-based Array BioPharma by Pfizer for $11.4 billion raises the Colorado financing total to $12.1 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Major financings contributed to the notable fundraising year for Colorado companies and institutions. Clovis Oncology raised $175 million in clinical trial financing and Inscripta closed $125 million in Series D financing to fund commercialization of its digital genome engineering platform.

Additionally, more than 40 companies and institutions in Colorado received federal grants including funds from the National Institutes of Health (NIH), the U.S. Air Force and Small Business Innovative Research (SBIR) grants from the Small Business Administration. The University of Colorado, National Jewish Health and Colorado State University were the state’s largest recipients of federal grants, all from the National Institutes of Health.

Jennifer Jones Paton, President & CEO of Colorado BioScience Association, says:

"Our ecosystem’s track record of successful financings and acquisitions highlights the global impact made by companies and organizations from Colorado. Life sciences breakthroughs from our state change and save lives around the world. The record-breaking acquisition and successful fundraising demonstrate the strong interest in Colorado’s thriving life sciences ecosystem."

Emily Roberts, Vice President of Colorado BioScience Association, says:

"We are proud of the companies in our ecosystem that landed Advanced Industries Grants from the state of Colorado. These funds are critical for our start-up and mid-stage companies as they seek to prove out concepts and move into commercialization. We are committed to advocating for this important state funding of our innovators and job creators."

The State of Colorado awarded 16 Advanced Industries grants to Colorado life sciences companies in 2019, with grants ranging from $20,000-$250,000. As a designated Advanced Industry in Colorado, the life sciences ecosystem makes a significant contribution to the state’s diverse and fast-growing economy, creating high-paying jobs for more than 89,000 Coloradans.

Colorado BioScience Association works actively on capital and growth initiatives to accelerate investment in our state’s life sciences ecosystem. While robust, Colorado’s percentage of funding per capita lags behind bioscience clusters in California and Massachusetts.

On December 17, 2019 Sengenics, a leading commercial stage precision medicine focused company, reported that Dr Arif Anwar, CEO of Sengenics, has been invited to present at the Biotech Showcase during the upcoming 38th Annual J.P. Morgan Healthcare Conference week in San Francisco (Press release, Sengenics, DEC 17, 2019, View Source [SID1234552443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Arif Anwar will present an overview of the commercialisation strategy of the company, as well as applications of its well-differentiated and patented KREX technology for intra-disease stratification and autoimmune and cancer immunotherapy drug response prediction. The identity of the autoantibody biomarkers discovered from these applications can also guide drug development decision-making for the pharmaceutical industry, allowing for the early elimination of poor drug candidates. For clinical stage candidates, this can result in very significant cost savings as well as acceleration of the best candidates towards faster FDA drug approval. For commercially launched drugs, KREX offers unparalleled opportunities to gain market share by identifying new true responders.

Sengenics currently has partnerships with 9 out of the top 20 pharma to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2020. Sengenics’ key value drivers, which are derivatives from enhancing precision medicine, are primarily based on maximising the probability that drugs are prescribed only to patients who have a greater than 90% chance of responding to them. These new Sengenics tests offer a compelling business case for the pharmaceutical industry as well as medical insurance companies, whilst ultimately delivering upon the promise of precision medicine for autoimmune and cancer immunotherapy drugs.

Details of Sengenics’ presentation are as follows:

Event: Biotech Showcase 2020

Date: Tuesday, January 14, 2020

Time: 2:30 PM Pacific Time (5:30 PM Eastern Time)

Title: Realising the Potential of Precision Medicine for Autoimmune and Cancer Drugs using Sengenics’ KREX Technology

Location: Franciscan B (Ballroom Level), Hilton San Francisco Union Square – 333 O’Farrell Street

The presentation document will be available on the Sengenics website in the "Downloads" section on the same day.

On December 17, 2019 Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease and Einstein Medical Center, the largest independent academic medical center in Philadelphia, reported the first patient enrolled in a study that compares OVA1 to CA125 assay for detection of ovarian cancer risk in African American women (Press release, Vermillion, DEC 17, 2019, View Source [SID1234552442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study will enroll over 200 prospective African American women with adnexal masses. Ovarian cancer risk will be assessed by both CA125 and OVA1 Plus. The primary objective is to determine the differences in sensitivity and accuracy of cancer risk detection between the testing methodologies. The study is to be expanded to women of varying ethnic backgrounds as well.

"African American women have lower incidence of ovarian cancer than Caucasian women, yet a higher all-cause mortality rate," said Lead Investigator Kate Stampler, D.O., Department of Obstetrics and Gynecology at Einstein Medical Center Philadelphia. "Recent evidence demonstrates that they also have lower levels of CA125 that could lead to underdiagnosis."

Recently published studies demonstrate that OVA1 has greater sensitivity in detecting ovarian cancer across multiple ethnicities and technologies including CA125 and ROMA:

OVA1 in African American women is 2.38-times more sensitive than CA125: 79.2% v 33.3%1
OVA1 in African American women is 1.45-times more sensitive than ROMA: 79.1% v 54.5%2
OVA1 in Caucasian women is more sensitive than CA125: 93.2% v 74.4%1
OVA1 in Caucasian women is more sensitive than ROMA: 93.2% v 82.9%2
"This study should confirm that OVA1 provides more sensitive risk detection in African American women. It may also define differences in sensitivity amongst various ethnicities and races," said Charles Dunton, MD, Global Medical Director, Vermillion. "This study can help address the disparities in diagnosis and outcomes of ovarian cancer in African American women."

OVA1 is an FDA-cleared and ACOG-endorsed blood test offered via ASPiRA Labs. OVA1 proactively assesses the risk of ovarian malignancy from a simple blood test, as a pre-operative biopsy is not medically appropriate. Clinically, OVA1 objectively guides the patient treatment care plan for low-risk and high-risk pelvic mass patients.